Cullinan: Zipalertinib+Chemo Shows 6-Month PFS Benefit in EGFR NSCLC

Cullinan reported positive Phase 3 REZILIENT3 results where zipalertinib plus chemotherapy significantly improved progression-free survival in first-line EGFR exon 20 insertion NSCLC. The data, presented at WCLC, supported the therapy's efficacy. These results are highly relevant for the company's pipeline and oncology sector.